US challenges 'bogus' patents on Ozempic and other drugs in effort to spur competition
Time:2024-05-21 20:40:27 Source:politicsViews(143)
WASHINGTON (AP) — Federal regulators are challenging patents on 20 brand name drugs, including the blockbuster weight-loss injection Ozempic, in the latest action by the Biden administration targeting industry practices that drive up pharmaceutical prices.
The Federal Trade Commission on Tuesday sent warning letters to 10 drugmakers, taking issue with patents on popular drugs for weight loss, diabetes, asthma and other reparatory conditions. The letters allege that certain patents filed by Novo Nordisk, GlaxoSmithKline, AstraZeneca and seven other companies are inaccurate or misleading.
Brand-name drugmakers use patents to protect their medicines and stave off cheaper, generic medicines. Most blockbuster drugs are protected by dozens of patents covering various ingredients, manufacturing processes and intellectual property. Generic drugmakers can only launch their own cheaper versions if the patents have expired or are successfully challenged in court.
Previous:Baby Reindeer's real
Next:Iran helicopter crash that killed President Raisi could reverberate across the Middle East
You may also like
- China's first intelligent offshore drilling platform installed
- Ancient tomb unveiled: discoveries from Western Zhou Dynasty
- 2024 Pudong Festival of Culture & Art opens next week
- China urges Philippines to stop provocations in South China Sea
- Saudi Arabia is going to sponsor the WTA women's tennis rankings under a new partnership
- Death toll from Moscow terror attack rises to 93
- Andrew Scott speaks out on his 'wonderful' friendship with All Of Us Strangers co
- Drake pushes back after Rick Ross accused him of getting a nose job in Champagne Moments lyrics
- Ricky Stenhouse punching Kyle Busch could lead to suspension